Odomzo (sonidegib) 200mg
What is Odomzo (sonidegib) 200mg ?
Odomzo (sonidegib) 200mg is an oral medication used to treat a type of skin cancer called basal cell carcinoma. Sonidegib is an inhibitor of the hedgehog biological signaling pathway, a pathway that promotes the growth of both normal and cancer cells.
Odomzo (sonidegib) 200mg is used to treat basal cell carcinoma (a type of skin cancer).
Odomzo (sonidegib) 200mg is usually given when surgery or radiation cannot be used, or have been used without success.
How to use sonidegib ?
The recommended dose of sonidegib is 200 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal. Sonidegib may be taken until the cancer progresses or unacceptable toxicity develops.
Side effects of sonidegib
The most common side effects of sonidegib include
muscle pain and spasms, and itching.
Women taking sonidegib may experience an absence of menstrual periods (amenorrhea). It is not known if amenorrhea is permanent. Women who wish to get pregnant in the future should talk to their doctor for advice.
Sonidegib is broken down by a group of liver enzymes known as cytochrome P4503A (CYP3A). Sonidegib should not be combined with drugs that inhibit the activity of these enzymes because enzyme inhibition may result in high blood levels of sonidegib, leading to increased side effects. Examples of such inhibitors include
certain HIV medications,
telithromycin (Ketek), and
Similarly, sonidegib should be combined with drugs that induce (increase the activity) of CYP3A enzymes. Strong CYP3A inducers may decrease blood levels of sonidegib causing treatment failure. Examples of CYP3A inducers include
rifampin (Rimactane) .